Fig 1.
Description of the study population and each risk score assessment groups.
n, frequency; M, Male; F, Female; SBP, systolic blood pressure; HDL-C, high density lipoprotein-cholesterol; WHO-CVD, World Health Organization cardiovascular disease risk charts; CVD, cardiovascular disease; DM, type 2 diabetes mellitus; BMI, body mass index; MI, myocardial infarction; CHD, coronary heart disease; PAD, peripheral arterial disease;.
Table 1.
Characteristics of APCAPS participants (follow-up 3) considered for WHO- and GLOBORISK-CVD-risk prediction scores calculation (n = 2465).
Table 2.
Levels of CIMT, PWV and AIx across the categories of WHO-CVD and GLOBORISK scores as well as β coeff. (95% CI) for CIMT, PWV and AIx per SD change in CVD scores.
Table 3.
Agreement between the lab- and non-lab-based WHO- and GLOBORISK-CVD-risk prediction scores.
Table 4.
Mean difference and limits of agreement for the Bland-Altman analysis.